ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
September 30, 2021

Prof. Sylviane Muller awarded prestigious Legion d’honneur.’

Read More
September 29, 2021

Corporate Update

Read More
September 29, 2021

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2021

Read More
August 24, 2021

Director & PDMR Share Purchases

Read More
August 17, 2021

Lanstead Capital TR1

Read More
August 12, 2021

FDA approves the Lupzuor™ PK study

Read More
July 30, 2021

BOARD CHANGES

Read More
July 16, 2021

BOARD APPOINTMENT

Read More
June 28, 2021

2021 RESULT OF ANNUAL GENERAL MEETING – ALL RESOLUTIONS PASSED

Read More
June 24, 2021

FDA to agree on the Lupzuor™ PK study via a written response to “Type

Read More
June 02, 2021

Notice of AGM and posting of Report & Accounts

Read More
May 24, 2021

Director Retirement

Read More
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 24
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved